USSTOCK.TODAY
Market Closed
Log in Sign up

Verrica Pharmaceuticals Announces YCANTH Sales and VP-315 Development Plan

The Motley Fool +1 · ·by G4L

VRCA
VRCA Verrica Pharmaceuticals Inc
$3.56 -4.30%
View chart & analysis →
  1. 1Verrica Pharmaceuticals recorded $5.7 million in net product sales for YCANTH in the third quarter of 2026 in the United States.
  2. 2Verrica Pharmaceuticals announced a development plan for VP-315 to treat Gorlin syndrome.
  3. 3Verrica Pharmaceuticals secured an additional $15 million in capital following the end of the quarter.

So what's the key point?

Verrica Pharmaceuticals generated $5.7 million in sales from YCANTH and revealed plans to develop a new treatment. The company also raised an additional $15 million in funding.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Snail, Inc. Records $33.1 Million in Q3 Net Revenue The Motley Fool +1 · 36m agoPEDEVCO Corp. Records $35.5 Million in Q3 Revenue and Rocky Mountain Asset Conversion The Motley Fool +1 · 36m agoNeovolta Starts Fendragrass Manufacturing Facility Operations and Revenue Recovers The Motley Fool +1 · 39m ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news